Alan Raises €480M Series G, Valued at €5.5B

Paris-based healthtech innovator, Alan, has successfully closed a substantial Series G funding round, bringing in €480 million. This significant capital infusion propels the company's valuation to an impressive €5.5 billion, underscoring its rapid ascent in the digital health landscape. The round was spearheaded by global investment powerhouse Prosus, with strong participation from existing investors Index Ventures and Teachers' Venture Growth, alongside new entrant Dara Holdings.

Since its inception in 2016, Alan has evolved from a digital health insurer into a comprehensive health ecosystem. The platform now seamlessly integrates insurance, direct care provision, and preventative health services, leveraging an AI-native architecture. This technological foundation is key to Alan's strategy of delivering highly personalized healthcare experiences while maintaining lean operational growth, a critical differentiator in the often-labor-intensive healthcare sector.

The company's financial performance is a testament to its disruptive model. Alan reported over €800 million in annual recurring revenue as of the first quarter of 2026, marking a robust 53% year-on-year expansion. Serving more than 1.1 million individuals, Alan has achieved profitability in its primary market, France, signaling strong product-market fit and operational efficiency.

Prosus, a prominent investor in high-growth technology companies, has indicated its intention to actively support Alan's international expansion initiatives. Furthermore, Prosus plans to accelerate Alan's product development pipeline, particularly by integrating its advanced AI capabilities, including its proprietary Large Commerce Model, into Alan's offerings. This strategic alignment highlights the growing recognition of AI's transformative potential in healthcare.

Jean-Charles Samuelian-Werve, co-founder and CEO of Alan, expressed enthusiasm about the funding's implications. He stated that this capital injection will empower the company to expedite its growth trajectory, enabling expansion into new geographies, deepening its presence in existing markets, and significantly increasing investments in AI and product innovation. Samuelian-Werve, who also co-founded the notable AI firm Mistral, emphasized Alan's core competitive advantage: an unwavering dedication to refining product and user experience within an industry ripe for modernization.

The broader healthtech market is experiencing significant investor interest, driven by increasing demand for accessible, efficient, and personalized healthcare solutions. Companies like Alan are at the forefront of this transformation, utilizing technology to address systemic inefficiencies. The recent funding round for Alan positions it as a key player poised to redefine healthcare delivery across Europe and beyond, potentially setting new benchmarks for digital health platforms in terms of scale, profitability, and patient-centricity.

This significant funding round, which is subject to customary regulatory approvals, signals continued confidence in Alan's vision and execution. The company's ability to achieve such a high valuation while demonstrating profitability and rapid revenue growth is a compelling narrative in the current venture capital climate, particularly within the competitive European tech ecosystem.